natgillin/translations-raw huggingface dataset:
For instructions on reconstitution and radiolabelling of the medicinal product before administration, see section 12.
Za navodila za rekonstitucijo in radioaktivno označevanje pred dajanjem zdravila glejte poglavje 12.
For instructions on reconstitution and radiolabelling of the medicinal product before administration, see sections 12.
Za navodila o rekonstituciji in radioaktivnem označevanju zdravila pred dajanjem glejte poglavje 12.
For instructions on reconstitution of Herceptin intravenous formulation before administration, see section 6.6.
Za navodila glede rekonstitucije zdravila Herceptin v intravenski obliki pred dajanjem glejte poglavje 6.6.
For instructions on reconstitution of the medicinal product before administration, see section 6.6 and the package leaflet.
Za navodila glede rekonstitucije zdravila pred uporabo glejte poglavje 6.6 in navodilo za uporabo.
For instructions on reconstitution of the medicinal product before administration, see section 6.6.
Za navodila glede rekonstrukcije zdravila pred dajanjem, glejte poglavje 6.6.
For instructions on reconstitution of the medicinal product before administration, see section 6.6.
Za navodila o rekonstituiranju zdravila pred uporabo glejte poglavje 6.6.
For instructions on reconstitution of the medicinal product before administration, see section 6.6. Adjunctive therapy
Za navodila glede rekonstrukcije zdravila pred dajanjem glejte poglavje 6.6. Dodatno zdravljenje
For instructions on reconstitution of the medicinal product before administration, see section 6.6. Administer the solution as an intravenous bolus injection over 2 – 5 minutes.
Za navodila o pripravi raztopine pred uporabo glejte poglavje 6.6. Raztopino aplicirajte v 2- do 5- minutni intravenski bolusni injekciji.
For instructions on reconstitution of the medicinal product before administration, see section 6.6. Only plastic luer-lock syringes should be used with this product.
Za navodila glede rekonstitucije zdravila pred dajanjem glejte poglavje 6.6. Za zdravilo uporabljajte le plastične brizge z luer lock nastavkom.
For instructions on reconstitution of the medicinal product before administration, see section 6.6. The reconstituted preparation should be injected slowly intravenously at a rate comfortable for the patient up to a maximum of 5 ml/min.
Za navodila glede rekonstitucije zdravila pred dajanjem glejte poglavje 6.6. Rekonstituirano zdravilo je treba injicirati počasi intravensko s hitrostjo, udobno za bolnika do največ 5 ml/min.
For instructions on reconstitution of the medicinal product before administration, see section.6.6.
Za navodila glede rekonstitucije zdravila pred dajanjem glejte poglavje 6.6.
For instructions on reconstitution of the medicinal product prior to administration, see section 6.6.
Za navodila o pripravi zdravila pred uporabo glejte poglavje 6.6.
For instructions on reconstitution prior to administration, see section 6.6
Pred uporabo preberite navodila za pripravo, glejte poglavje 6.6
For instructions on reconstitution prior to administration, see section 6.6.
Pred uporabo preberite navodila za pripravo, glejte poglavje 6.6
For instructions on the dilution of the medicinal product before administration, see section 6.6. Good peripheral venous access, or a patent central line, should be ensured prior to administration.
Za navodila glede redčenja zdravila pred dajanjem glejte poglavje 6.6. Pred dajanjem se prepričajte, da obstaja dober periferni venski dostop ali prehodna centralna linija.
For instructions on the dilution of the medicinal product before administration, see section 6.6. The withdrawn amount of concentrate must be further diluted in 100 ml of sterile 0.9% w/v sodium chloride solution or 5% w/v glucose solution.
Za navodila glede redčenja zdravila pred dajanjem glejte poglavje 6.6. Odvzeto količino koncentrata morate dodatno razredčiti v 100 ml sterilne 0,9-odstotne m/v raztopine natrijevega klorida ali 5- odstotne m/v raztopine glukoze.
For instructions on the dilution of the medicinal product before administration, see section 6.6. The withdrawn amount of concentrate must be further diluted in 100 ml of sterile sodium chloride 9 mg/ml (0.9%) solution for injection or 5% w/v glucose solution.
Za navodila glede rekonstitucije in redčenja zdravila pred dajanjem glejte poglavje 6.6. Odvzeto količino koncentrata je potrebno dodatno redčiti v 100 ml 9 mg/ml (0,9%) sterilne raztopine natrijevega klorida za injiciranje ali 5-odstotne (m/m) raztopine glukoze.
For instructions on the dilution of the medicinal product before administration, see section 6.6. The withdrawn amount of the solution for infusion must be further diluted to 100 ml using sterile sodium chloride 9 mg/ml (0.9%) solution for injection or 5% w/v glucose solution.
Za navodila glede redčenja zdravila pred dajanjem glejte poglavje 6.6. Odvzeto količino raztopine za infundiranje morate dodatno redčiti v 100 ml z uporabo sterilne 9 mg/ml (0,9-odstotne) raztopine natrijevega klorida za injekcije ali 5-odstotne m/v raztopine glukoze.
For instructions on the dilution of zoledronic acid before administration, see section 6.6. The withdrawn amount of concentrate must be further diluted in 100 ml of sterile 0.9% w/v sodium chloride solution or 5% w/v glucose solution.
Za navodila glede redčenja zoledronske kisline pred dajanjem glejte poglavje 6.6. Odvzeto količino koncentrata morate dodatno razredčiti v 100 ml sterilne 0,9-odstotne m/v raztopine natrijevega klorida ali 5-odstotne m/v raztopine glukoze.
For instructions on the handling of the medicinal product before administration, see section 6.6.
Za navodila za ravnanje z zdravilom pred uporabo glejte poglavje 6.6.
For instructions on the preventive measures and monitoring of hypersensitivity reactions, see section 4.4. Following the occurrence of a hypersensitivity reaction, appropriate pre-treatment should be considered according to the standard of care (see section 4.4).
Za navodila glede preventivnih ukrepov in spremljanja preobčutljivostnih reakcij glejte poglavje 4.4. Po pojavu preobčutljivostne reakcije je treba razmisliti o ustrezni premedikaciji v skladu s standardno nego (glejte poglavje 4.4).
For instructions on the reconstitution and administration of GONAL-f powder and solvent for solution for injection see section 6.6 and the package leaflet.
Za navodila o rekonstituciji in dajanju zdravila GONAL-f prašek in vehikel za raztopino za injiciranje glejte poglavje 6.6 in navodilo za uporabo.
For instructions on use and handling of Herceptin subcutaneous formulation, refer to section 6.6 of the SmPC, and section 7 of the package leaflet.
Za navodila za pripravo in ravnanje s subkutano obliko zdravila Herceptin glejte poglavje 6.6 Povzetka glavnih značilnosti zdravila in poglavje 7 Navodila za uporabo.
For instructions on use and handling of the reconstituted solution, see section 6.6.
Navodila za uporabo in ravnanje z rekonstituirano raztopino so v poglavju 6.6.
For instructions to implant the lumbar interbody fusion device, please refer to the manufacturer’s instructions for use.
Navodila za implantacijo vstavka za interkorpusno fuzijo ledvene hrbtenice poiščite v izdelovalčevem navodilu za uporabo.
For instructions, see below.
Glejte spodnja navodila.
For instrutions for use, see section 4.2: Posology and method of administration.
Za navodila za ravnanje glejte poglavje 4.2: Odmerjanje in način uporabe.
For insulin glargine no clinical data on exposed pregnancies from controlled clinical studies are available.
Za insulin glargin ni na voljo kliničnih podatkov iz nadzorovanih kliničnih preskušanj nosečnic, ki so bile izpostavljene zdravilu.
For insulin glargine no clinical data on exposed pregnancies from controlled clinical studies are available.
Za insulin glargin ni na voljo kliničnih podatkov iz nadzorovanih kliničnih preskušanj od nosečnic.
for INTELENCE is
(odmerek maraviroka je
For intradermal use.
Za intradermalno uporabo
FOR INTRAMUSCULAR ADMINISTRATION
ZA INTRAMUSKULARNO UPORABO
For intramuscular use after reconstitution with solvent.
Za intramuskularno uporabo po rekonstituciji z vehiklom.
For intramuscular use of 1 dose (2 ml) per pig.
1 odmerek (2 ml) na prašiča apliciramo intramuskularno.
For intramuscular use.
intramuskularma uporaba
For intramuscular use.
Intramuskularna uporaba
For intramuscular use.
Intramuskularno dajanje.
For intranasal/ocular, spray or drinking water administration.
Za intranazalno/okularno dajanje, razprševanje ali dajanje v vodi za pitje
For intravenous administration.
Za intravensko uporabo.
For intravenous bolus injection a solution with a concentration of 5 mg/ml is needed:
Za intravensko bolusno injekcijo potrebujemo raztopino v koncentraciji 5 mg/ml:
For intravenous infusion after reconstitution and dilution
Za intravensko infuzijo po pripravi in redčenju.
For intravenous infusion after reconstitution and dilution.
intravensko infundiranje po rekonstituciji in redčenju
For intravenous infusion only
Samo za intravensko infuzijo
For intravenous injection only!
Samo za intravensko injiciranje
For intravenous or subcutaneous use.
Za intravensko in subkutano uporabo.
For intravenous use
Ig) za intravensko uporabo
For intravenous use
Za intravensko uporabo.
For intravenous use after dilution
Za intravensko uporabo po razredčenju
For intravenous use after dilution
Za intravensko uporabo po razredčenju.
For intravenous use after dilution
Za intravensko uporabo po razredčitvi
For intravenous use after dilution Do not shake
Za intravensko uporabo po razredčenju Ne stresajte
For intravenous use after dilution Read the package leaflet before use
Za intravensko uporabo po razdredčitvi Pred uporabo preberite priloženo navodilo
For intravenous use after dilution Read the package leaflet before use
Za intravensko uporabo po razredčitvi Pred uporabo preberite priloženo navodilo
For intravenous use after dilution.
intravenska uporaba po razredčenju
For intravenous use after reconstitution and dilution
za intravensko uporabo po pripravi in redčenju
For intravenous use after reconstitution and dilution Read the package leaflet before use
za intravensko uporabo po pripravi in redčenju Pred uporabo preberite priloženo navodilo
For intravenous use after reconstitution and dilution.
Za intravensko infundiranje po rekonstituciji in redčenju.
For intravenous use after reconstitution and further dilution.
Za intravensko uporabo po rekonstituciji in nadaljnjem razredčenju.
For intravenous use after reconstitution Read the package leaflet before use.
za intravensko uporabo po rekonstituciji Pred uporabo preberite priloženo navodilo
For intravenous use after reconstitution with 10 ml solvent
za intravensko uporabo po pripravi z 10 ml vehikla
For intravenous use after reconstitution with 10 ml solvent Read the package leaflet before use.
za intravensko uporabo po pripravi z 10 ml vehikla Pred uporabo preberite priloženo navodilo
For intravenous use after reconstitution with 8 ml solvent
za intravensko uporabo po pripravi z 8 ml vehikla
For intravenous use after reconstitution with 8 ml solvent Read the package leaflet before use.
za intravensko uporabo po pripravi z 8 ml vehikla Pred uporabo preberite priloženo navodilo
For intravenous use Not for bolus injection
Ni primerno za bolusno injekcijo.
For intravenous use only after reconstitution and dilution Read the package leaflet before use.
Za intravensko uporabo le po rekonstituciji in razredčitvi Pred uporabo preberite priloženo navodilo
For intravenous use only.
intravenska uporaba
For intravenous use only.
Samo za enkratno uporabo.
For intravenous use only.
samo za intravensko uporabo
For intravenous use over 15 - 30 seconds, every three months.
Za intravensko uporabo v 15 do 30 sekundah, vsake tri mesece.
For intravenous use, infusion systems with Actrapid at concentrations from 0.05 international unit/ml to 1.0 international unit/ml human insulin in the infusion fluids 0.9% sodium chloride, 5% dextrose and 10% dextrose inclusive 40 mmol/l potassium chloride using polypropylene infusion bags, are stable at room temperature for 24 hours.
Pri intravenski uporabi so infuzijski sistemi iz polipropilenskih vrečk, ki vsebujejo zdravilo Actrapid v koncentraciji od 0,05 mednarodne enote/ml do 1,0 mednarodne enote/ml humanega insulina v infuzijskih tekočinah z 0,9 % natrijevega klorida, s 5 % glukoze ali z 10 % glukoze ter s koncentracijo kalijevega klorida 40 mmol/l, pri sobni temperaturi stabilni 24 ur.
For intravenous use.
intravenska uporaba
For intravenous. bolus injection a solution with a concentration of 5 mg/ml is needed:
Za intravensko bolusno injekcijo potrebujemo raztopino v koncentraciji 5 mg/ml:
For Intravenouse Use.
Za intravensko uporabo.
For intravitreal injection use only.
Samo za intravitrealno uporabo.
For introduction of the carbon dioxide into the analyser many sample inlet systems are available.
Za uvajanje ogljikovega dioksida v analizator je na voljo veliko sistemov za dovod vzorcev.
For ipilimumab-related uveitis, iritis, or episcleritis, topical corticosteroid eye drops should be considered as medically indicated.
Pri z ipilimumabom povzročenem uveitisu, iritisu ali episkleritisu bo morda indicirana topikalna uporaba kortikosteroidov v obliki kapljic za oko.
For Ipreziv, olmesartan medoxomil and valsartan, respectively dizziness was observed at an incidence of 3.0%, 3.3% and 1.8%; headache at 4.8%, 5.5% and 7.6% and
Za zdravilo Ipreziv, medoksomilolmesartanat in valsartan je bila omotica opažena s pogostnostjo 3,0 %, 3,3 % in 1,8 %, glavobol s pogostnostjo 4,8 %, 5,5 % in 7,6 % ter dislipidemija s pogostnostjo 3,5 %, 2,4 % in 1,1 %.
For Irbesartan/Hydrochlorothiazide Teva packaged in aluminium – aluminium blisters: This medicinal product does not require any special storage conditions.
Za zdravilo Irbesartan/hidroklorotiazid Teva v aluminij – aluminijevih pretisnih omotih: : Za shranjevanje zdravila niso potrebna posebnia navodila.
For Irbesartan/Hydrochlorothiazide Teva packaged in aluminium – aluminium blisters: This medicinal product does not require any special storage conditions.
Za zdravilo Irbesartan/hidroklorotiazid Teva v aluminij – aluminijevih pretisnih omotih: Za shranjevanje zdravila niso potrebna posebna navodila.
For Irbesartan/Hydrochlorothiazide Teva packaged in white opaque PVC-PVdC – aluminium blisters: Do not store above 30°C.
Za zdravilo Irbesartan/hidroklorotiazid Teva v belih neprozornih PVC-PVdC - aluminijevih pretisnih omotih: Shranjujte pri temperaturi do 30°C.
for ISENTRESS.
ISENTRESS ni treba
for itraconazole can be made,
priporočila za odmerjanje, je treba
For ITT; n=736, 721 for subcutaneous (SC) and intravenous (IV) abatacept, respectively
Za vse vključene bolnike: n=736 za subkutano (s.c.) uporabo abatacepta in n=721 za intravensko (i.v.) uporabo abatacepta.
For IV use after dilution.
Za i.v. uporabo po redčenju.
For IV use after reconstitution and dilution
Za i.v. uporabo po rekonstituciji in redčenju.
For IV use only
Samo za i.v. uporabo
For joints reported as recurring in a previous study, the day of recurrence was the first visit with a fixed flexion contracture measurement of 20° or greater following the report of recurrence. c The nominal rate of recurrence was the total number of recurrences occurring prior to the last day of the interval divided by the total number of joints (×100).
Za sklepe, pri katerih je bila ponovitev poročana v prejšnji študiji, je bil dan ponovitve prvi obisk s popravljeno izmerjeno fleksijsko kontrakturo 20° ali več po poročani ponovitvi. c Nominalni delež ponovitve je bil celotno število ponovitev, ki se je pojavile pred zadnjim dnem intervala, deljeno s številom sklepov (×100).
For Kaletra oral solution, the corresponding increases in lopinavir AUC and Cmax were 80% and 54%, respectively.
Pri peroralni raztopini Kaletra je bilo ustrezno zvečanje AUC lopinavirja 80%, Cmax pa 54%.
For Kaposi’s sarcoma, around 70% of the patients had a complete or partial response to treatment, with similar results in the study of patients who had been treated before.
Pri zdravljenju Kaposijevega sarkoma se je približno 70 % bolnikov popolnoma ali delno odzvalo na zdravljenje, podobni rezultati pa so bili doseženi tudi v študiji z bolniki, ki so se že prej zdravili.
For laboratory abnormalities, very common events (1/10) not included in Table 2 are also reported.
Navedene so tudi zelo pogoste (1/10) laboratorijske nepravilnosti, ki niso vključene v preglednico 2.
For lamivudine, the EC50 values against HIV-1 subtypes (A-G) ranged from 0.001 to 0.170 M, against Group O from 0.030 to 0.160 M and against HIV-2 isolates from 0.002 to 0.120 M in peripheral blood mononuclear cells.
Za lamivudin so v mononuklearnih celicah periferne krvi vrednosti EC50 proti podtipom HIV-1 (A-G) segale od 0,001 do 0,170 M, proti skupini O od 0,030 do 0,160 M in proti izolatom HIV-2 od 0,002 do 0,120 M.
For lamivudine, the IC50 values against HIV-1 subtypes (A-G) ranged from 0.001 to 0.170 M, against Group O from 0.030 to 0.160 M and against HIV-2 isolates from 0.002 to 0.120 M in peripheral blood mononuclear cells.
Za lamivudin so v mononuklearnih celicah periferne krvi vrednosti IC50 proti podtipom HIV-1 (A-G) segale od 0,001 do 0,170 M, proti skupini O od 0,030 do 0,160 M in proti izolatom HIV-2 od 0,002 do 0,120 M.
For laparoscopy, see Section 4.4.
Za laparoskopijo glejte poglavje 4.4.
for large cats
Za velike mačke
For large cats > 5 kg – 8 kg
Za velike mačke > 5 kg – 8 kg
for large cats >6.25 – 12.5 kg
za velike mačke >6,25 – 12,5 kg
For large cats weighing between 4 kg and 8 kg.
Za velike mačke od 4 – 8 kg telesne mase.
for large dogs
za velike pse
for Large Dogs (25.1 – 40.0 kg)
za velike pse (25,1 – 40,0 kg)
for large dogs (>20 –40 kg)
za velike pse >20-40 kg
for large dogs >20 – 40 kg
za velike pse >20-40 kg
For larger dogs it can be applied in up to four different spots along the back from the shoulders to the base of the tail.
Večjim psom lahko zdravilo nanesemo na največ štiri mesta vzdolž hrbtenice od ramen do korena repa.
For larger dogs, apply the contents of the pipette evenly to two (medium dogs) or three (large dogs) or four (very large dogs) spots, all located at different application sites along the backline from the shoulder to the base of the tail.
Za velike pse nanesite vsebino merilne kapalke enakomerno na dve (srednje veliki psi) ali tri (veliki psi) ali štiri (zelo veliki psi) mesta na različnih mestih vzdolž hrbtenice od ramen do korena repa.
For lenvatinib related toxicities (see Table 1), upon resolution/improvement of an adverse reaction to Grade 0-1 or baseline, treatment should be resumed at a reduced dose of lenvatinib as suggested in Table 2.
Pri toksičnostih, povezanih z lenvatinibom (glejte preglednico 1), naj se po tistem, ko neželeni učinek izzveni ali se izboljša na stopnjo 0-1 ali v izhodišče, zdravljenje spet začne z zmanjšanim odmerkom lenvatiniba v skladu s preglednico 2.
for life threatening cardiac
ogrožajoče srčne aritmije je to
for life threatening cardiac
zdravilo kontraindicirano z
for life threatening cardiac
zdravilom Invirase/ritonavir (glejte
for life threatening cardiac
zdravilom Invirase/ritonavirjem
For life-threatening bleeding that cannot be controlled with the measures such as transfusion or haemostasis, the administration of a 4-factor prothrombin complex concentrate (PCC) at 50 IU/kg has been shown to reverse the effects of Lixiana 30 minutes after completing the infusion.
Pri smrtno nevarni krvavitvi, ki je ne moremo obvladati s transfuzijo ali hemostazo, so pokazali, da uporaba koncentrata protrombinskega kompleksa s 4 faktorji (PCC) v odmerku 50 i.e./kg nevtralizira učinke zdravila Lixiana 30 minut po končani infuziji.
For liquids, gastric emptying t1/2 increased from 0.28 h to 0.69 h (p=0.0018).
Za tekočine se je t1/2 praznjenja želodca podaljšal z 0,28 ure na 0,69 ure (p = 0,0018).
for liver problems
za zdravljenje težav z jetri
For long periods of bed rest due to an illness
Po daljšem okrevanju v postelji zaradi bolezni
For long term prophylaxis against bleeding in patients below the age of 12, doses of 25-50 IU of factor VIII per kg body weight every second day or 25-60 IU of factor VIII per kg body weight 3 times weekly are recommended.
Za dolgotrajno profilakso krvavitev pri bolnikih, mlajših od 12 let, so priporočljivi odmerki 25-50 i.e. faktorja VIII na kg telesne mase vsak drugi dan ali 25-60 i.e. faktorja VIII na kg telesne mase 3-krat na teden.
For long term prophylaxis against bleeding in patients with severe haemophilia A, the usual doses for adolescents (≥ 12 years age) and adult patients are 20 to 40 IU of Kovaltry per kg body weight two to three times per week.
Za dolgotrajno preprečevanje krvavitev pri bolnikih s hudo obliko hemofilije A so običajni odmerki za mladostnike (≥ 12 let) in odrasle bolnike od 20 do 40 i.e. zdravila Kovaltry na kg telesne mase dva- do trikrat na teden.
For long term prophylaxis against bleeding in patients with severe haemophilia A. The usual recommended doses are 20-40 IU of factor VIII per kg body weight every second day or 20-50 IU of factor VIII per kg body weight 3 times weekly.
Za dolgotrajno profilakso krvavitev pri bolnikih s hudo hemofilijo A so običajni priporočeni odmerki 20- 40 i.e. faktorja VIII na kg telesne mase vsak drugi dan ali 20-50 i.e. faktorja VIII na kg telesne mase 3-krat na teden.
For long term prophylaxis in patients with severe haemophilia A, the usual dose is 20 to
Za dolgotrajno profilakso krvavitev pri bolnikih s hudo hemofilijo A so običajni odmerki 20 do 40 i.e.
For long-term prevention of bleeding in individuals with severe haemophilia B, doses of 20 IU to 40 IU of factor IX per kilogram body weight should be given at intervals of 3 to 4 days.
Za dolgoročno preprečevanje krvavitev pri posameznikih s hudo hemofilijo B je treba dajati odmerke 20 i.e. do 40 i.e. faktorja IX na kilogram telesne mase v intervalih 3 do 4 dni.
For long-term prophylaxis against bleeding in patients with severe haemophilia A, the usual doses are 20 to 40 IU of factor VIII per kg body weight at intervals of 2 to 3 days.
Za dolgoročno preprečevanje krvavitev pri bolnikih s hudo hemofilijo A znašajo običajni odmerki od 20 do 40 i.e. faktorja VIII na kg telesne mase na vsake 2 do 3 dni.
For long-term prophylaxis of haemorrhages in patients with severe haemophilia B, doses of 20 to 40 IU of factor IX per kilogram of body weight could be given at intervals of 3 to 4 days.
Za dolgoročno preprečevanje krvavitev in njenih posledic pri bolnikih s hudo hemofilijo B lahko dajemo odmerke 20 i.e. do 40 i.e. faktorja IX na kilogram telesne mase v intervalih 3 do 4 dni.
For long-term treatment, once a clinical response has been observed, the dose of Onsior can be adjusted to the lowest effective individual dose reflecting that the degree of pain and inflammation associated with chronic osteoarthritis may vary over time.
Pri dolgotrajnem zdravljenju lahko po vidnem kliničnem odgovoru odmerek Onsiorja prilagodimo na najnižji učinkovit individualen odmerek, pri tem pa upoštevamo, da se stopnja bolečine in vnetja, povezana s kroničnim osteoartritisom, lahko spreminja.
For long-term treatment, once a clinical response has been observed, the dose of Onsior can be adjusted to the lowest effective individual dose reflecting that the degree of pain and inflammation associated with chronic osteoartritis may vary over time.
Pri dolgotrajnem zdravljenju lahko po vidnem kliničnem odgovoru odmerek Onsiorja prilagodimo na najnižji učinkovit individualen odmerek, pri tem pa upoštevamo, da se stopnja bolečine in vnetja, povezana s kroničnim osteoartritisom, lahko spreminja.
For longer term treatment, once clinical response has been observed (after ≥ 4 days), the dose of Inflacam can be adjusted to the lowest effective individual dose reflecting that the degree of pain and inflammation associated with chronic musculo-skeletal disorders may vary over time.
Za daljše zdravljenje, ko je klinični odziv že opazen (po ≥ 4 dneh), se odmerek Inflacama lahko prilagodi na najnižji individualni odmerek, ki učinkuje na zmanjšanje bolečine in vnetja pri kroničnih mišično- skeletnih obolenj, ki se s časom lahko spremeni.